The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular ...

Christopher Burston’s bowel cancer appeared to disappear after just nine weeks of immunotherapy, yet he still underwent ...

Researchers discovered that recurring arthritis triggered by cancer immunotherapy may be driven by immune cells that remember ...

“AI model developed to predict liver cancer immunotherapy effectiveness from a single drop of blood” ...

Two new studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide new insight into how the ...

Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or ...

The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...

Jemperli (dostarlimab) is a PD-1 blocking immunotherapy designed to help the body's immune system recognize and attack cancer cells. The drug is already approved for certain gynecological cancers and ...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, announced that three ...

Identify cancer immunotherapy opportunities, pitfalls and companies poised to benefit, with CAR-T, checkpoint inhibitor and cytokine insights for confident investment decisions.Dublin, Oct. 15, 2026 ...

Targeted immunotherapy is a new direction in precision cancer therapy, with many approvals for T-cell engagers (TCEs) in hematologic malignancies. The recent approvals of tebentafusp and tarlatamab ...